BioPharma Dive

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...
Business Wire

Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational ...
vator

N-Power Medicine raises Series B funding, partners with Merck

Only 5% of cancer patients enroll in oncology clinical trials today because the majority of oncologists don’t participate in clinical research, especially in the community setting, where 85% of cancer ...
The Motley Fool

Is Merck Stock a Buy?

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these ...
Morningstar

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an ...
sharewise

J&J or Merck? Key Factors Investors Must Weigh Right Now

Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct ...